Loading...

Veracyte, Inc.

VCYT•NASDAQ
Healthcare
Biotechnology
$41.19
$8.22(24.93%)
U.S. Market opens in 0h 21m

Veracyte, Inc. (VCYT) Stock Overview

Explore Veracyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap3.3B
P/E Ratio37.36
EPS (TTM)$1.08
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$31.74
3 Months$25.15
1 Year Target$45.32

VCYT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Veracyte, Inc. (VCYT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 73.71, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $45.32.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 37.36 and a market capitalization of 3.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
24.93%
5-Day Change
24.93%
1-Month Change
27.44%
3-Month Change
13.82%
6-Month Change
-1.20%
Year-to-Date (YTD) Change
-2.16%
1-Year Change
34.78%
3-Year Change
82.02%
5-Year Change
-5.98%
All-Time (Max) Change
210.87%

Contact Information

https://www.veracyte.com
650 243 6300
6000 Shoreline Court, South San Francisco, CA, 94080

Company Facts

824 Employees
IPO DateOct 30, 2013
CountryUS
Actively Trading

Frequently Asked Questions